MX2017011399A - Métodos para modular la densidad ósea. - Google Patents
Métodos para modular la densidad ósea.Info
- Publication number
- MX2017011399A MX2017011399A MX2017011399A MX2017011399A MX2017011399A MX 2017011399 A MX2017011399 A MX 2017011399A MX 2017011399 A MX2017011399 A MX 2017011399A MX 2017011399 A MX2017011399 A MX 2017011399A MX 2017011399 A MX2017011399 A MX 2017011399A
- Authority
- MX
- Mexico
- Prior art keywords
- bone density
- methods
- modulating bone
- subject
- preventing
- Prior art date
Links
- 230000037182 bone density Effects 0.000 title abstract 3
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 230000008468 bone growth Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 230000011164 ossification Effects 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
- C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562130144P | 2015-03-09 | 2015-03-09 | |
| PCT/US2016/021344 WO2016144946A1 (en) | 2015-03-09 | 2016-03-08 | Methods for modulating bone density |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2017011399A true MX2017011399A (es) | 2018-03-16 |
Family
ID=56879295
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017011399A MX2017011399A (es) | 2015-03-09 | 2016-03-08 | Métodos para modular la densidad ósea. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20180042943A1 (enExample) |
| EP (1) | EP3268009A4 (enExample) |
| JP (1) | JP2018507880A (enExample) |
| KR (1) | KR20170125927A (enExample) |
| CN (1) | CN107530361A (enExample) |
| AU (1) | AU2016229906A1 (enExample) |
| CA (1) | CA2978916A1 (enExample) |
| HK (1) | HK1243646A1 (enExample) |
| IL (1) | IL254197A0 (enExample) |
| MX (1) | MX2017011399A (enExample) |
| SG (1) | SG11201707328SA (enExample) |
| WO (1) | WO2016144946A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201812382D0 (en) | 2018-07-30 | 2018-09-12 | Nzp Uk Ltd | Compounds |
| US10919162B2 (en) | 2018-12-26 | 2021-02-16 | Ford Global Technologies, Llc | Systems and methods for efficient power management of modular mobile robot platforms with replaceable batteries |
| DE102020101118A1 (de) | 2019-01-18 | 2020-07-23 | Ford Global Technologies, Llc | Mobile mehrzweckroboter und verfahren zu deren verwendung |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003223214B2 (en) * | 2002-03-01 | 2008-09-18 | Celltech R & D, Inc. | Methods to increase or decrease bone density |
| WO2003080803A2 (en) * | 2002-03-21 | 2003-10-02 | Smithkline Beecham Corporation | Methods of using farnesoid x receptor (fxr) agonists |
| CL2007003035A1 (es) * | 2006-10-24 | 2008-05-16 | Smithkline Beechman Corp | Compuestos derivados de isoxazol sustituidos, agonistas de receptores farnesoid x; procedimiento de preparacion; composicion farmaceutica que lo comprende; y uso del compuesto en el tratamiento de la obesidad, diabetes mellitus, fibrosis en organos, |
| JP2012072095A (ja) * | 2010-09-29 | 2012-04-12 | Tokyo Institute Of Technology | 骨形成促進剤 |
| ES2822375T3 (es) * | 2012-06-19 | 2021-04-30 | Intercept Pharmaceuticals Inc | Preparación de la forma no cristalina del ácido obeticólico |
| WO2014021694A1 (ko) * | 2012-08-03 | 2014-02-06 | 서울대학교 산학협력단 | 골 관련 질환 예방 및 치료를 위한 조성물 |
| HRP20180931T1 (hr) * | 2013-05-14 | 2018-10-05 | Intercept Pharmaceuticals, Inc. | 11-hidroksil-6-supstituirani-derivati žučnih kiselina i njihovi aminokiselinski konjugati kao modulatori receptora za farnezoid x |
-
2016
- 2016-03-08 KR KR1020177027942A patent/KR20170125927A/ko not_active Withdrawn
- 2016-03-08 CA CA2978916A patent/CA2978916A1/en not_active Abandoned
- 2016-03-08 AU AU2016229906A patent/AU2016229906A1/en not_active Abandoned
- 2016-03-08 SG SG11201707328SA patent/SG11201707328SA/en unknown
- 2016-03-08 HK HK18103269.8A patent/HK1243646A1/zh unknown
- 2016-03-08 US US15/556,514 patent/US20180042943A1/en not_active Abandoned
- 2016-03-08 WO PCT/US2016/021344 patent/WO2016144946A1/en not_active Ceased
- 2016-03-08 EP EP16762337.0A patent/EP3268009A4/en not_active Withdrawn
- 2016-03-08 JP JP2017547148A patent/JP2018507880A/ja active Pending
- 2016-03-08 CN CN201680022614.7A patent/CN107530361A/zh active Pending
- 2016-03-08 MX MX2017011399A patent/MX2017011399A/es unknown
-
2017
- 2017-08-29 IL IL254197A patent/IL254197A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2016229906A1 (en) | 2017-09-21 |
| CA2978916A1 (en) | 2016-09-15 |
| US20180042943A1 (en) | 2018-02-15 |
| HK1243646A1 (zh) | 2018-07-20 |
| JP2018507880A (ja) | 2018-03-22 |
| WO2016144946A1 (en) | 2016-09-15 |
| SG11201707328SA (en) | 2017-10-30 |
| IL254197A0 (en) | 2017-10-31 |
| CN107530361A (zh) | 2018-01-02 |
| KR20170125927A (ko) | 2017-11-15 |
| EP3268009A4 (en) | 2018-12-12 |
| EP3268009A1 (en) | 2018-01-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB2541571A (en) | Pharmaceutical compositions | |
| MX2022007221A (es) | Compuestos y composiciones para el tratamiento o prevencion de trastornos patologicos asociados con exceso de deposicion de fibrina y/o formacion de trombos. | |
| MX2018004947A (es) | Metodos para el tratamiento de sindrome de angelman y de los trastornos relacionados. | |
| MX2017008844A (es) | Terapia de combinacion con inhibidor de acetil-coa carboxilasa (acc) para el tratamiento de enfermedad de higado graso no alcoholico. | |
| MX2017005252A (es) | Metodos para la preparacion de ribosidos. | |
| EA201891340A1 (ru) | Лечение рака с использованием 2-дезокси-2-фтор-l-фукозы в комбинации с ингибитором контрольных точек | |
| EA201790142A1 (ru) | Лечение лейкоза ингибиторами гистондеацетилазы | |
| MD20170073A2 (ro) | Terapii combinate pentru tratarea cancerelor | |
| MA40458A (fr) | Méthodes de traitement du cancer du col de l'utérus | |
| EP4289820A3 (en) | Compounds for use in treating alzheimer's disease in apoe4+/+ patients | |
| MX2016015378A (es) | Uso de eribulina en el tratamiento de cancer. | |
| MX379271B (es) | Compuestos desestabilizadores de microtubulina para usarse en el tratamiento del cáncer. | |
| PH12015502815A1 (en) | Use of sigma receptor ligands for the prevention and treatment of pain associated to interstitial cystitis/bladder pain syndrome (ic/bps) | |
| JO3541B1 (ar) | علاجات طبية قائمة على اناموريلين | |
| MX2017000306A (es) | Metodos para tratar hipotension. | |
| MX2017016114A (es) | Metodos para tratar o prevenir una proteopatia. | |
| MX378931B (es) | Metodos para tratar y prevenir enfermedades de inestabilidad vascular. | |
| MX2017011399A (es) | Métodos para modular la densidad ósea. | |
| MX2020001164A (es) | Composicion para su uso en la prevencion y/o el tratamiento de la mucositis orogastrointestinal inducida por un tratamiento oncologico. | |
| MX382930B (es) | Tratamiento con cis-clomifeno de sofocos y pérdida ósea inducidos por privación de andrógeno terapéutica. | |
| TW201613639A (en) | Methods for treating cardiovascular diseases | |
| TW201613569A (en) | Composition consisting of kukoamine A and/or kukoamine B and method of using thereof | |
| MY198753A (en) | Treatment of androgen deprivation therapy associated symptoms | |
| EP3881845A3 (en) | Combination of trazodone and gabapentin for the treatment of pain | |
| PH12014501044A1 (en) | Methods for improved wound closure employing olivamine and human umbilical vien endothelial cells |